We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adjuvant radiotherapy in FIGO 2023 stage I-II endometrial cancer with intermediate and high-intermediate risk.
- Authors
Jae Hong No; Kyunghee Han; Min Kyung Kim; Dong Hoon Suh; Kidong Kim; Yong Beom Kim
- Abstract
Objective: The aim of this study is to assess the survival outcomes associated with adjuvant radiotherapy in patients with early-stage endometrial cancer with intermediate and high-intermediate risk. Methods: We conducted a retrospective review of medical data for 168 patients diagnosed with 2023 FIGO stage I and II endometrial cancer. All these patients underwent surgery between 2003 and 2021. The risk scoring was based on ESMO-ESCO-ESTRO criteria. Univariate and multivariate logistic analyses were employed to assess prognostic factors. For progression-free survival and overall survival analyses, the Kaplan-Meier method with log-rank test and Cox proportional hazard analysis were utilized. Results: The median age of total patients was 57 years (range, 27-81), and the median follow-up period was 63.1 months (range, 2.4-232.1). Among the study population, 59 individuals (35.1%) received adjuvant radiotherapy. In radiation group, twenty-one patients (35.6%) underwent vaginal brachytherapy, and thirtyfive patients (59.3%) underwent external beam radiation therapy. The proportion of patients with intermediate risk and highintermediate risk was higher in the radiation group (n=29, 70.7%; n=59, 35.3%, respectively). In multivariate analyses, both tumor grade 3 and over 50% myometrial invasion were associated with disease recurrence (p=0.003, p<0.001, respectively). Kaplan-Meier curves revealed that survival did not exhibit significant differences regardless of adjuvant radiotherapy (progression-free survival, p=0.756; overall survival, p=0.683, respectively). There were three cases of complication following adjuvant radiation, all of which were diagnosed as radiation colitis. Conclusion: Despite the radiation group exhibiting poor prognostic factors, our study concluded that there was no significant difference in progression-free and overall survival between the two groups.
- Subjects
RADIOTHERAPY; ENDOMETRIAL cancer; EXTERNAL beam radiotherapy; OVERALL survival; PROGRESSION-free survival; PROGNOSIS
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, p53
- ISSN
2005-0380
- Publication type
Article
- DOI
10.3802/jgo.2024.35.S2.P65